H1 total sales growth of 11.4% at CER1, or 9.7% as reported, driven by the three therapeutic areas: 95.7% in Rare Disease, ...

H1 total sales growth of 11.4% at CER1, or 9.7% as reported, driven by the three therapeutic areas: 95.7% in Rare Disease, 9.7% in Neuroscience, and 6.4% in OncologyH1 core operating income of €656m, ...

Women across Uganda have been urged to prioritize early childhood immunization against Hepatitis B, with health officials warning that failure to vaccinate children at birth puts future generations at ...